Forest, TransTech sign licensing deal for diabetes drug

06/8/2010 | Wall Street Journal, The · Bloomberg Businessweek

Forest Laboratories signed a license agreement with TransTech Pharma to develop and commercialize glucose-lowering agents for diabetes. The deal, worth as much as $1.11 billion, will give Forest exclusive rights to the resulting treatment in international markets except the Middle East and North Africa, where TransTech will keep its license.

View Full Article in:

Wall Street Journal, The · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD